Protein kinase inhibitors

ABSTRACT

The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.

FIELD OF INVENTION

The present invention relates to a novel family of inhibitors of proteinkinases. In particular, the present invention relates to inhibitors ofthe members of the Tec and Src protein kinase families, moreparticularly Btk.

BACKGROUND OF THE INVENTION

Protein kinases are a large group of intracellular and transmembranesignaling proteins in eukaryotic cells. These enzymes are responsiblefor transfer of the terminal (gamma) phosphate from ATP to specificamino acid residues of target proteins. Phosphorylation of specifictyrosine, serine or threonine amino acid residues in target proteins canmodulate their activity leading to profound changes in cellularsignaling and metabolism. Protein kinases can be found in the cellmembrane, cytosol and organelles such as the nucleus and are responsiblefor mediating multiple cellular functions including metabolism, cellulargrowth and division, cellular signaling, modulation of immune responses,and apoptosis. The receptor tyrosine kinases are a large family of cellsurface receptors with protein tyrosine kinase activity that respond toextracellular cues and activate intracellular signaling cascades(Plowman et al. (1994) DN&P, 7(6):334-339).

Aberrant activation or excessive expression of various protein kinasesare implicated in the mechanism of multiple diseases and disorderscharacterized by benign and malignant proliferation, excessangiogenesis, as well as diseases resulting from inappropriateactivation of the immune system. Thus, inhibitors of select kinases orkinase families are expected to be useful in the treatment of cancer,autoimmune diseases, and inflammatory conditions including, but notlimited to: solid tumors, hematological malignancies, arthritis, graftversus host disease, lupus erythematosus, psoriasis, colitis, illeitis,multiple sclerosis, uveitis, coronary artery vasculopathy, systemicsclerosis, atherosclerosis, asthma, transplant rejection, allergy,dermatomyositis, pemphigus and the like.

Examples of kinases that can be targeted to modulate disease includereceptor tyrosine kinases such as members of the platelet-derived growthfactor receptor (PDGFR), vascular endothelial growth factor receptor(VEGFR) families and intracellular proteins such as members of the Syk,SRC, and Tec families of kinases.

Tec kinases are non-receptor tyrosine kinases predominantly, but notexclusively, expressed in cells of hematopoietic origin (Bradshaw JM.Cell Signal. 2010, 22:1175-84). The Tec family includes Tec, Bruton'styrosine kinase (Btk), inducible T-cell kinase (Itk), resting lymphocytekinase (Rlk/Txk), and bone marrow-expressed kinase (Bmx/Etk). Btk is aTec family kinase which is important in B-cell receptor signaling. Btkis activated by Src-family kinases and phosphorylates PLC gamma leadingto effects on B-cell function and survival. Additionally, Btk isimportant in signal transduction in response to immune complexrecognition by macrophage, mast cells and neutrophils. Btk inhibition isalso important in survival of lymphoma cells (Herman, S E M. Blood 2011,117:6287-6289) suggesting that inhibition of Btk may be useful in thetreatment of lymphomas. As such, inhibitors of Btk and related kinasesare of great interest as anti-inflammatory as well as anti-canceragents.

cSRC is the prototypical member of the SRC family of tyrosine kinaseswhich includes Lyn, Fyn, Lck, Hck, Fgr, Blk, Syk, Yrk, and Yes. cSRC iscritically involved in signaling pathways involved in cancer and isoften over-expressed in human malignancies (Kim L C, Song L, Haura E B.Nat Rev Clin Oncol. 2009 6(10):587-9). The role of cSRC in celladhesion, migration and bone remodeling strongly implicate this kinasein the development and progression of bone metastases. cSRC is alsoinvolved in signaling downstream of growth factor receptor tyrosinekinases and regulates cell cycle progression suggesting that cSRCinhibition would impact cancer cell proliferation. Additionally,inhibition of SRC family members may be useful in treatments designed tomodulate immune function. SRC family members, including Lck, regulateT-cell receptor signal transduction which leads to gene regulationevents resulting in cytokine release, survival and proliferation. Thus,inhibitors of Lck have been keenly sought as immunosuppressive agentswith potential application in graft rejection and T-cell mediatedautoimmune disease (Martin et al. Expert Opin Ther Pat. 2010,20:1573-93).

Inhibition of kinases using small molecule inhibitors has successfullyled to several approved therapeutic agents used in the treatment ofhuman conditions. Herein, we disclose a novel family of kinaseinhibitors. Further, we demonstrate that modifications in compoundsubstitution can influence kinase selectivity and therefore thebiological function of that agent.

SUMMARY OF THE INVENTION

The present invention relates to a novel family of kinase inhibitors.Compounds of this class have been found to have inhibitory activityagainst members of the Tec and Src protein kinase families, moreparticularly Btk.

One aspect of the present invention is directed to a compound of Formula1:

wherein

R is selected from the group consisting of:

-   -   1) hydrogen,    -   2) alkyl,    -   3) heteroalkyl,    -   4) carbocyclyl,    -   5) heterocyclyl;    -   wherein the alkyl, heteroalkyl, carbocyclyl and heterocyclyl may        be further substituted.

Y is

E is selected from oxygen,

Z is selected from:

Wherein Y-E-Z—W is

X¹ and X² are independently selected from hydrogen and halogen;n is an integer from 0 to 2;m is an integer from 0 to 2;m′ is an integer from 0 to 2;

W is independently selected from:

-   -   1) alkyl,    -   2) aralkyl,    -   3) heteroaralkyl,    -   4) —OR³,    -   5) —OC(O)R⁴,    -   6) —OC(O)NR⁵R⁶,    -   7) —CH₂O—R⁴,    -   8) —NR⁵R⁶,    -   9) —NR²C(O)R⁴    -   10) —NR²S(O)_(n)R⁴,    -   11) —NR²C(O)NR⁵R⁶;        wherein the alkyl, aralkyl and heteroaralkyl may be further        substituted;

R² is selected from hydrogen or alkyl;

R³ is selected from substituted or unsubstituted alkyl, alkenyl,alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl,aralkyl or heteroaralkyl;

R⁴ is selected from substituted or unsubstituted alkyl, alkenyl,alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl or heteroaryl; and

R⁵ and R⁶ are independently selected from hydrogen, alkyl, alkenyl,alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl or R⁵and R⁶ can be fused to form a 3 to 8 membered heterocyclyl ring system.

Preferred embodiments include compounds of Formula 1 where W is selectedfrom —OR³ and R³ is selected from substituted or unsubstituted aralkyl,or substituted or unsubstituted heteroaralkyl.

More preferred embodiments include compounds of Formula 1 where W isselected from the group consisting of:

Even more preferred embodiments include compounds of Formula 1 where Yis selected from the group consisting of:

Preferred embodiments include compounds of Formula 1 where Z is selectedfrom the group consisting of:

Preferred embodiment includes compounds of Formula 1 where R is selectedfrom the group consisting of:

More preferred embodiments include compounds of Formula 1 where W isselected from the group consisting of:

More preferred embodiments include compounds of Formula 1 where Z isselected from the group consisting of:

Another aspect of the present invention provides a pharmaceuticalcomposition comprising an effective amount of a compound of Formula 1and a pharmaceutically acceptable carrier, diluent or excipient.

In another aspect of the present invention, there is provided a use ofthe compound of Formula 1 as an inhibitor of protein kinase, moreparticularly, as an inhibitor of Btk.

Another aspect of the present invention provides a method of modulatingkinase function, the method comprising contacting a cell with a compoundof the present invention in an amount sufficient to modulate theenzymatic activity of a given kinase or kinases, such as Btk, therebymodulating the kinase function.

Another aspect of the present invention provides a method of modulatingthe target kinase function, the method comprising a) contacting a cellwith a compound of the present invention in an amount sufficient tomodulate the target kinase function, thereby b) modulating the targetkinase activity and signaling.

Another aspect of the present invention provides a probe, the probecomprising a compound of Formula 1 labeled with a detectable label or anaffinity tag. In other words, the probe comprises a residue of acompound of Formula 1 covalently conjugated to a detectable label. Suchdetectable labels include, but are not limited to, a fluorescent moiety,a chemiluminescent moiety, a paramagnetic contrast agent, a metalchelate, a radioactive isotope-containing moiety, or biotin.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention relates to novel kinase inhibitors. Thesecompounds are found to have activity as inhibitors of protein kinases,including members of the tyrosine kinases Aurora, SRC (more specificallyLck) and Tec (more specifically Btk) kinase families.

Compounds of the present invention may be formulated into apharmaceutical composition which comprises an effective amount of acompound of Formula 1 with a pharmaceutically acceptable diluent orcarrier. For example, the pharmaceutical compositions may be in aconventional pharmaceutical form suitable for oral administration (e.g.,tablets, capsules, granules, powders and syrups), parenteraladministration (e.g., injections (intravenous, intramuscular, orsubcutaneous)), drop infusion preparations, inhalation, eye lotion,topical administration (e.g., ointment), or suppositories. Regardless ofthe route of administration selected, the compounds may be formulatedinto pharmaceutically acceptable dosage forms by conventional methodsknown to those skilled in the art.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose ligands, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically acceptable carrier” as used herein means apharmaceutically acceptable material, composition, or vehicle, such as aliquid or solid filler, diluent, excipient, solvent or encapsulatingmaterial. Each carrier must be acceptable in the sense of beingcompatible with the other ingredients of the formulation, including theactive ingredient, and not injurious or harmful to the patient. Someexamples of materials which can serve as pharmaceutically acceptablecarriers include: (1) sugars, such as lactose, glucose, and sucrose; (2)starches, such as corn starch, potato starch, and substituted orunsubstituted β-cyclodextrin; (3) cellulose, and its derivatives, suchas sodium carboxymethyl cellulose, ethyl cellulose, and celluloseacetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8)excipients, such as cocoa butter and suppository waxes; (9) oils, suchas peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil,corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11)polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol;(12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14)buffering agents, such as magnesium hydroxide and aluminum hydroxide;(15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18)Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions;and (21) other non-toxic compatible substances employed inpharmaceutical formulations.

The term “pharmaceutically acceptable salt” refers to the relativelynon-toxic, inorganic and organic acid addition salts of the compound(s).These salts can be prepared in situ during the final isolation andpurification of the compound(s), or by separately reacting a purifiedcompound(s) in its free base form with a suitable organic or inorganicacid, and isolating the salt thus formed. Representative salts includethe hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate,acetate, valerate, oleate, palmitate, stearate, laurate, benzoate,lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate,tartrate, naphthylate, mesylate, glucoheptonate, lactobionate,laurylsulphonate salts, and amino acid salts, and the like (See, forexample, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19).

In other cases, the compounds of the present invention may contain oneor more acidic functional groups and, thus, are capable of formingpharmaceutically acceptable salts with pharmaceutically acceptablebases. The term “pharmaceutically acceptable salts” in these instancesrefers to the relatively non-toxic inorganic and organic base additionsalts of a compound(s). These salts can likewise be prepared in situduring the final isolation and purification of the compound(s), or byseparately reacting the purified compound(s) in its free acid form witha suitable base, such as the hydroxide, carbonate, or bicarbonate of apharmaceutically acceptable metal cation, with ammonia, or with apharmaceutically acceptable organic primary, secondary, or tertiaryamine. Representative alkali or alkaline earth salts include thelithium, sodium, potassium, calcium, magnesium, and aluminum salts, andthe like. Representative organic amines useful for the formation of baseaddition salts include ethylamine, diethylamine, ethylenediamine,ethanolamine, diethanolamine, piperazine, and the like (see, forexample, Berge et al., supra).

As used herein, the term “affinity tag” means a ligand or group, linkedeither to a compound of the present invention or to a protein kinasedomain, that allows the conjugate to be extracted from a solution.

The term “alkyl” refers to substituted or unsubstituted saturatedhydrocarbon groups, including straight-chain alkyl and branched-chainalkyl groups, including haloalkyl groups such as trifluoromethyl and2,2,2-trifluoroethyl, etc. Representative alkyl groups include methyl,ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl,(cyclohexyl)methyl, cyclopropylmethyl, n-pentyl, n-hexyl, n-heptyl,n-octyl, and the like. The terms “alkenyl” and “alkynyl” refer tosubstituted or unsubstituted unsaturated aliphatic groups analogous inlength and possible substitution to the alkyls described above, but thatcontain at least one double or triple bond respectively. Representativealkenyl groups include vinyl, propen-2-yl, crotyl, isopenten-2-yl,1,3-butadien-2-yl), 2,4-pentadienyl, and 1,4-pentadien-3-yl.Representative alkynyl groups include ethynyl, 1- and 3-propynyl, and3-butynyl. In certain preferred embodiments, alkyl substituents arelower alkyl groups, e.g., having from 1 to 6 carbon atoms. Similarly,alkenyl and alkynyl preferably refer to lower alkenyl and alkynylgroups, e.g., having from 2 to 6 carbon atoms. As used herein,“alkylene” refers to an alkyl group with two open valencies (rather thana single valency), such as —(CH₂)₁₋₁₀- and substituted variants thereof.

The term “alkoxy” refers to an alkyl group having an oxygen attachedthereto. Representative alkoxy groups include methoxy, ethoxy, propoxy,tert-butoxy and the like. An “ether” is two hydrocarbons covalentlylinked by an oxygen. Accordingly, the substituent of an alkyl thatrenders that alkyl an ether is or resembles an alkoxy.

The term “alkoxyalkyl” refers to an alkyl group substituted with analkoxy group, thereby forming an ether.

The terms “amide” and “amido” are art-recognized as an amino-substitutedcarbonyl and includes a moiety that can be represented by the generalformula:

wherein R⁹, R¹⁰ are as defined above. Preferred embodiments of the amidewill not include imides, which may be unstable.

The terms “amine” and “amino” are art-recognized and refer to bothunsubstituted and substituted amines and salts thereof, e.g., a moietythat can be represented by the general formulae:

wherein R⁹, R¹⁰ and R^(10′) each independently represent a hydrogen, analkyl, an alkenyl, —(CH₂)_(p)—R⁸, or R⁹ and R¹⁰ taken together with theN atom to which they are attached complete a heterocycle having from 4to 8 atoms in the ring structure; R⁸ represents an aryl, a cycloalkyl, acycloalkenyl, a heterocyclyl or a polycyclyl; and p is zero or aninteger from 1 to 8. In preferred embodiments, only one of R⁹ or R¹⁰ canbe a carbonyl, e.g., R⁹, R¹⁰ and the nitrogen together do not form animide. In even more preferred embodiments, R⁹ and R¹⁰ (and optionallyR^(10′)) each independently represent a hydrogen, an alkyl, an alkenyl,or —(CH₂)_(p)—R⁸. In certain embodiments, the amino group is basic,meaning the protonated form has a pK_(a)>7.00.

The term “aralkyl”, as used herein, refers to an alkyl group substitutedwith an aryl group, for example —(CH₂)_(p)—Ar.

The term “heteroaralkyl”, as used herein, refers to an alkyl groupsubstituted with a heteroaryl group, for example —(CH₂)_(p)—Het.

The term “aryl” as used herein includes 5-, 6-, and 7-memberedsubstituted or unsubstituted single-ring aromatic groups in which eachatom of the ring is carbon. The term “aryl” also includes polycyclicring systems having two or more cyclic rings in which two or morecarbons are common to two adjoining rings wherein at least one of therings is aromatic, e.g., the other cyclic rings can be cycloalkyls,cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline,anthracene, and phenanthrene.

The terms “carbocycle” and “carbocyclyl”, as used herein, refer to anon-aromatic substituted or unsubstituted ring in which each atom of thering is carbon. The terms “carbocycle” and “carbocyclyl” also includepolycyclic ring systems having two or more cyclic rings in which two ormore carbons are common to two adjoining rings wherein at least one ofthe rings is carbocyclic, e.g., the other cyclic rings can becycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/orheterocyclyls. Representative carbocyclic groups include cyclopentyl,cyclohexyl, 1-cyclohexenyl, and 3-cyclohexen-1-yl, cycloheptyl.

The term “carbonyl” is art-recognized and includes such moieties as canbe represented by the general formula:

wherein X is a bond or represents an oxygen or a sulfur, and R¹¹represents a hydrogen, an alkyl, an alkenyl, —(CH₂)_(p)—R⁸ or apharmaceutically acceptable salt. Where X is oxygen and R¹¹ is nothydrogen, the formula represents an “ester”. Where X is oxygen, and R¹¹is hydrogen, the formula represents a “carboxylic acid”.

The terms “heteroaryl” includes substituted or unsubstituted aromatic 5-to 7-membered ring structures, more preferably 5- to 6-membered rings,whose ring structures include one to four heteroatoms. The term“heteroaryl” also includes polycyclic ring systems having two or morecyclic rings in which two or more carbons are common to two adjoiningrings wherein at least one of the rings is heteroaromatic, e.g., theother cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls,aryls, heteroaryls, and/or heterocyclyls. Heteroaryl groups include, forexample, pyrrole, furan, thiophene, imidazole, isoxazole, oxazole,thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine andpyrimidine, and the like.

The term “heteroatom” as used herein means an atom of any element otherthan carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, andsulfur.

The terms “heterocyclyl” or “heterocyclic group” refer to substituted orunsubstituted non-aromatic 3- to 10-membered ring structures, morepreferably 3- to 7-membered rings, whose ring structures include one tofour heteroatoms. The term terms “heterocyclyl” or “heterocyclic group”also include polycyclic ring systems having two or more cyclic rings inwhich two or more carbons are common to two adjoining rings wherein atleast one of the rings is heterocyclic, e.g., the other cyclic rings canbe cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/orheterocyclyls. Heterocyclyl groups include, for example,tetrahydrofuran, tetrahydropyran, piperidine, piperazine, pyrrolidine,morpholine, lactones, and lactams.

The term “hydrocarbon”, as used herein, refers to a group that is bondedthrough a carbon atom that does not have a ═O or ═S substituent, andtypically has at least one carbon-hydrogen bond and a primarily carbonbackbone, but may optionally include heteroatoms. Thus, groups likemethyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to behydrocarbyl for the purposes of this application, but substituents suchas acetyl (which has a ═O substituent on the linking carbon) and ethoxy(which is linked through oxygen, not carbon) are not. Hydrocarbyl groupsinclude, but are not limited to aryl, heteroaryl, carbocycle,heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.

The terms “polycyclyl” or “polycyclic” refer to two or more rings (e.g.,cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/orheterocyclyls) in which two or more carbons are common to two adjoiningrings, e.g., the rings are “fused rings”. Each of the rings of thepolycycle can be substituted or unsubstituted.

As used herein, the term “probe” means a compound of the invention whichis labeled with either a detectable label or an affinity tag, and whichis capable of binding, either covalently or non-covalently, to a proteinkinase domain. When, for example, the probe is non-covalently bound, itmay be displaced by a test compound. When, for example, the probe isbound covalently, it may be used to form cross-linked adducts, which maybe quantified and inhibited by a test compound.

The term “substituted” refers to moieties having substituents replacinga hydrogen on one or more carbons of the backbone. It will be understoodthat “substitution” or “substituted with” includes the implicit provisothat such substitution is in accordance with permitted valence of thesubstituted atom and the substituent, and that the substitution resultsin a stable compound, e.g., which does not spontaneously undergotransformation such as by rearrangement, cyclization, elimination, etc.As used herein, the term “substituted” is contemplated to include allpermissible substituents of organic compounds. In a broad aspect, thepermissible substituents include acyclic and cyclic, branched andunbranched, carbocyclic and heterocyclic, aromatic and non-aromaticsubstituents of organic compounds. The permissible substituents can beone or more and the same or different for appropriate organic compounds.For purposes of this invention, the heteroatoms such as nitrogen mayhave hydrogen substituents and/or any permissible substituents oforganic compounds described herein which satisfy the valences of theheteroatoms. Substituents can include, for example, a halogen, ahydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl,or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or athioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, aphosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro,an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, asulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or anaromatic or heteroaromatic moiety. It will be understood by thoseskilled in the art that the moieties substituted on the hydrocarbonchain can themselves be substituted, if appropriate.

Compounds of the invention also include all isotopes of atoms present inthe intermediates and/or final compounds. Isotopes include those atomshaving the same atomic number but different mass numbers. For example,isotopes of hydrogen include deuterium and tritium.

General Synthetic Methods

The following section describes general synthetic method(s) which may beuseful in the preparation of compounds of the instant invention.

General Synthetic Method A:

General Synthetic Method B:

EXAMPLES

The following synthetic methods are intended to be representative of thechemistry used to prepare compounds of Formula 1 and are not intended tobe limiting.

Synthesis of Intermediate 2-c:

Step 1: Intermediate 2-b

To a solution of cyclopentanone (12.73 g, 151.0 mmol) in dry benzene(15.2 ml) was added methyl 2-cyanoacetate (15.0 g, 151.0 mmol), ammoniumacetate (1.52 g, 19.68 mmol) and acetic acid (3.04 ml). The reactionmixture was heated to reflux in a Dean-Stark apparatus for 12 hours andthen cooled to room temperature. Volatiles were removed in vacuo. Waterand ethyl acetate were added to the residue, the organic layer wasseparated, washed with water, dried over MgSO₄, filtered andconcentrated under reduced pressure to provide intermediate 2-b as brownoil.

Step 2: Intermediate 2-c

To a solution of intermediate 2-b (25.0 g, 151.0 mmol) in methanol,stirred under nitrogen, was added 10% Pd/C (3.22 g, 1.51 mmol). Thereaction mixture was purged with H₂, stirred overnight under 1 atm ofhydrogen and filtered through celite. The filtrate was concentrated invacuo to provide intermediate 2-c as a yellow oil.

Synthesis of Intermediate 3-d:

Step 1: Intermediate 3-b

To a solution of resorcinol (11.83 g, 107 mmol) in DMF (50 ml) cooled to0° C. was added imidazole (15.36 g, 226 mmol) andtert-butylchlorodimethylsilane (17.0 g, 113 mmol). The reaction wasstirred at room temperature overnight. A saturated aqueous solution ofammonium chloride and ethyl acetate were added; the organic layer wasseparated, washed 3 times with a saturated aqueous solution of ammoniumchloride and brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 3-b as a colorless oil.

Step 2: Intermediate 3-c

To a solution of intermediate 3-b (1.94 g, 8.68 mmol) andthiazol-5-ylmethanol (1.0 g, 8.68 mmol) in THF (20 ml) were sequentiallyadded triphenylphosphine (3.42 g, 13.0 mmol) and DIAD (2.52 ml, 13.0mmol) and the reaction was then stirred at room temperature overnight.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 3-c as a yellow oil.

Step 3: Intermediate 3-d

To a solution of intermediate 3-c (1.6 g, 4.98 mmol) in THF (20 ml) wasadded a 1.0 M solution of TBAF in THF (5.47 ml, 5.47 mmol) and thereaction was stirred at room temperature for 1 hour. A saturated aqueoussolution of ammonium chloride and ethyl acetate were added, the organiclayer was separated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure. Diethyl ether was added to theresidue; a precipitate formed and was collected by filtration to provideintermediate 3-d as a white solid.

Synthesis of Intermediate 4-d:

Step 1: Intermediate 4-b

To a solution of 4-iodoaniline (13.14 g, 60.0 mmol) in 1N HCl (150 ml)was added dropwise a 1.0 M aqueous solution of sodium nitrite (60.0 ml,60.0 mmol) at room temperature, the mixture was stirred for 1 hour andthen added dropwise to an ice cooled solution of intermediate 2-c (5.0g, 29.9 mmol) in ethanol (41.7 ml) and water (556 mL). The pH wasmaintained at 7 by adding sodium acetate portion wise. The mixture wasstirred at 0° C. for 3 hours and then room temperature until completion.A saturated aqueous solution of ammonium chloride and ethyl acetate wereadded, the organic layer was separated, washed with brine, dried overMgSO₄, filtered and concentrated under reduced pressure to provideintermediate 4-b as a beige oil.

Step 2: Intermediate 4-c

To a solution of intermediate 4-b (7.0 g, 17.6 mmol) in THF (176 ml)cooled to 0° C. was added 10N aqueous NaOH (44.1 ml, 441.0 mmol) and thereaction was stirred at room temperature overnight. A saturated aqueoussolution of ammonium chloride and ethyl acetate were added, the organiclayer was separated, washed with 10% citric acid, saturated aqueousNaHCO₃ and brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 4-c as a yellow solid.

Step 3: Intermediate 4-d

To a solution of intermediate 4-c (2.1 g, 6.19 mmol) andbromoacetonitrile (474 μl, 6.81 mmol) in tert-butanol (31.0 ml) wasadded a 1.0 M solution of sodium tert-butoxide in tert-butanol (6.19 ml,6.19 mmol). The reaction was then stirred at room temperature for 2hours. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure.Purification by silica gel chromatography provided intermediate 4-d as ayellow solid.

Synthesis of Compound 1:

Step 1: Intermediate 2-1

To a solution of intermediate 3-d (125 mg, 0.60 mmol) and intermediate4-d (200 mg, 0.60 mmol) in 1,4-dioxane were sequentially addedN,N-dimethylglycine (37 mg, 0.36 mmol), cesium carbonate (393 mg, 1.20mmol) and copper(I) iodide (23 mg, 0.12 mmol). The reaction was stirredat reflux overnight and then cooled to room temperature. Water and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure toprovide intermediate 5-a as a brown solid.

Step 11: Compound 1

To a solution of intermediate 5-a (150 mg, 0.32 mmol) in EtOH (3.0 ml)was added formamidine acetate (265 mg, 2.54 mmol) and the reaction wasstirred at 80° C. for 3 hours, then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 1.2HCl as white solid. MS (m/z) M+H=485.2

Synthesis of Intermediate 6-c:

Step 1: Intermediate 6-b

To a solution of intermediate 6-a (5.05 g, 50.5 mmol) in dry benzene(5.0 ml) was added methyl 2-cyanoacetate (5.0 g, 50.5 mmol), ammoniumacetate (506 mg, 6.56 mmol) and acetic acid (1.0 ml). The reactionmixture was heated to reflux, using a Dean-Stark apparatus, for 12 hoursand then cooled to room temperature. Volatiles were removed in vacuo.Water and ethyl acetate were added to the residue, the organic layer wasseparated, washed with water, dried over MgSO₄, filtered andconcentrated under reduced pressure to provide intermediate 6-b as abrown oil.

Step 2: Intermediate 6-c

To a solution of intermediate 6-b (9.0 g, 49.7 mmol) in methanol, undernitrogen, was added 10% Pd/C (1.06 g, 0.49 mmol). The reaction mixturewas purged with H₂ and stirred overnight under 1 atm of hydrogen. Thereaction was then filtered through celite and the filtrate wasconcentrated under reduced pressure to provide intermediate 6-c as ayellow oil.

Synthesis of Intermediate 7-d:

Step 1: Intermediate 7-b

Ethyl chloroacetate (50.0 g, 0.41 mol) and ethyl formate (30.2 g, 0.41mol) were dissolved in anhydrous toluene (500 mL) and cooled to 0° C.Sodium ethoxide (35.1 g, 0.49 mol) was added portion wise. The reactionmixture was stirred at 0° C. for 5 hours and then at room temperatureovernight. The reaction mixture was quenched with water (250 mL) andwashed twice with diethyl ether. The aqueous layer was cooled to 0° C.and acidified to pH 4-5 using 1N aqueous HCl. The aqueous layer wasextracted twice with diethyl ether and the combined organic extractswere dried over MgSO₄, filtered and concentrated under reduced pressureto provide intermediate 7-b as a beige oil.

Step 2: Intermediate 7-c

To a solution of ethyl 2-chloro-3-oxopropanoate, 7-b (34.7 g, 230 mmol)in toluene (250 ml) was added thioacetamide (26.0 g, 346.0 mmol). Thereaction was stirred at 90° C. overnight and then cooled to roomtemperature, diluted with water (300 mL) and then neutralized to pH=7with saturated aqueous NaHCO₃. Ethyl acetate was added, the organiclayer was separated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure. Purification by silica gelchromatography provided intermediate 7-c as a beige oil.

Step 3: Intermediate 7-d

To a solution of intermediate 7-c (22.2 g, 130.0 mmol) in THF (430 ml)cooled to 0° C. was added a 1.0 M solution LiAlH₄ in THF (91.0 ml, 91.0mmol). The solution was slowly warmed to room temperature and stirredfor 2 hours. Water (3.5 ml) was slowly added, followed by 3.5 ml 15%NaOH (3.5 ml) and water (10.5 ml) and the mixture was stirred for 1hour. The reaction was filtered through celite and the filtratecollected. Volatiles were removed in vacuo to provide intermediate 7-das a yellow oil.

Synthesis of Intermediate 8-e:

Step 1: Intermediate 8-b

To a solution of 1-fluoro-3,5-dimethoxybenzene (12.5 g, 80.0 mmol) indichloromethane (80 ml), cooled to 0° C., was added a 1.0 M solution ofBBr₃ in dichloromethane (200 ml, 200 mmol), dropwise over a 30 minutesperiod. The reaction was stirred for 1 hour at 0° C. and then slowlywarmed to room temperature and stirred for 18 hours. The reaction wascooled to 0° C. and quenched by slow addition of MeOH and water. Afterstirring at room temperature for 1 hour the mixture was filtered andvolatiles were removed in vacuo. The solid was washed twice with ethylacetate; the filtrate was concentrated in vacuo to provide intermediate8-b as an orange solid.

Step 2: Intermediate 8-c

To a solution of intermediate 8-b (10.25 g, 80.0 mmol) in DMF (50 ml),cooled to 0° C., was added imidazole (5.99 g, 88.0 mmol) andtert-butylchlorodimethylsilane (13.27 g, 88.0 mmol). The reaction wasthen stirred at room temperature overnight. A saturated aqueous solutionof ammonium chloride and ethyl acetate were added; the organic layer wasseparated, washed 3 times with a saturated aqueous solution of ammoniumchloride and brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 8-c as a yellow oil.

Step 3: Intermediate 8-d

To a solution of intermediate 8-c (1.0 g, 105.0 mmol) and intermediate7-d (352 mg, 2.73 mmol) in THF (20 ml) were sequentially addedtriphenylphosphine (1.07 g, 4.1 mmol) and DIAD (796 μl, 4.1 mmol) atroom temperature. The reaction was then stirred at room temperature for1 hour. Volatiles were removed under reduced pressure. Purification bysilica gel chromatography provided intermediate 8-d as a yellow oil.

Step 4: Intermediate 8-e

To a solution of intermediate 8-d (750 mg, 1.57 mmol) in THF (20 ml) wasadded a 1.0 M solution of TBAF in THF (1.72 ml, 1.72 mmol) and thereaction was stirred at room temperature for 1 hour. A saturated aqueoussolution of ammonium chloride and ethyl acetate were added, the organiclayer was separated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure. Diethyl ether was added to theresidue; a precipitate formed and was collected by filtration to provideintermediate 8-e as a white solid.

Synthesis of Intermediate 9-d:

Step 1: Intermediate 9-b

To a solution of 4-bromoaniline (8.43 g, 49.0 mmol) in 1N aqueous HCl(123 ml) was added dropwise 1.0 M aqueous sodium nitrite (49.0 ml g,49.0 mmol) at room temperature. The mixture was stirred for 1 hour andthen added dropwise to an ice cooled solution of intermediate 6-c (4.5g, 24.56 mmol) in ethanol (34.30 ml) and water (457 mL). The pH wasmaintained at 7 by adding sodium acetate portion wise. The mixture wasstirred at 0° C. for 3 hours and then at room temperature untilcompletion. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure toprovide intermediate 9-b as a beige oil.

Step 2: Intermediate 9-c

To a solution of intermediate 9-b (10.0 g, 27.3 mmol) in THF (273 ml),cooled to 0° C., was added 10N aqueous NaOH (68.3 ml, 683.0 mmol) andthe reaction was stirred at room temperature for 2 hours. A saturatedaqueous solution of ammonium chloride and ethyl acetate were added, theorganic layer was separated, washed with 10% citric acid, saturatedaqueous NaHCO₃ and brine, dried over MgSO₄, filtered and concentratedunder reduced pressure. Purification by silica gel chromatographyprovided intermediate 9-c as a yellow solid.

Step 3: Intermediate 9-d

To a solution of intermediate 9-c (4.0 g, 12.98 mmol) andbromoacetonitrile (995 μl, 14.28 mmol) in tert-butanol (64.9 ml), cooledto 0° C. was added a 1.0 M solution of potassium tert-butoxide intert-butanol (27.3 ml, 27.3 mmol) and the reaction was stirred at roomtemperature for 2 hours. A saturated aqueous solution of ammoniumchloride and ethyl acetate were added, the organic layer was separated,washed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 9-d as a beige solid.

Synthesis of Compound 3:

Step 1: Intermediate 10-a

To a solution of intermediate 8-e (138 mg, 0.57 mmol) and intermediate9-d (200 mg, 0.57 mmol) in 1,4-dioxane were sequentially addedN,N-dimethylglycine (36 mg, 0.35 mmol), cesium carbonate (375 mg, 1.15mmol) and copper(I) iodide (22 mg, 0.11 mmol). The reaction was stirredat reflux overnight and then cooled to room temperature. Water and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure toprovide intermediate 10-a as a brown solid.

Step 13: Compound 3

To a solution of intermediate 10-a (291 mg, 0.57 mmol) in EtOH (6.0 ml)was added formamidine acetate (479 mg, 4.60 mmol) and the reaction wasstirred at 80° C. for 3 hours and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 3.2HCl as a white solid. MS (m/z) M+H=533.1

Synthesis of Intermediate 11-d:

Step 1: Intermediate 11-b

To a solution of 3,5-difluorophenol (15.0 g, 115 mmol) in acetone (200ml) was added K₂CO₃ (23.90 g, 173 mmol) and chloromethyl methyl ether(15.85 g, 127 mmol). The reaction was then stirred at room temperatureovernight and filtered. The filtrate was concentrated under reducedpressure to provide intermediate 11-b as a colorless oil.

Step 2: Intermediate 11-c

To a solution of (1-methyl-1H-imidazol-5-yl) methanol (3.1 g, 27.6 mmol)and intermediate 11-b (4.01 g, 23.04 mmol) in toluene (25.0 ml) and DMPU(25.0 ml) was added sodium 2-methylpropan-2-olate (4.43 g, 46.1 mmol).The reaction was stirred overnight at 80° C. and then cooled to roomtemperature. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed twice with asaturated aqueous solution of ammonium chloride and brine, dried overMgSO₄, filtered and concentrated in vacuo. Purification by silica gelchromatography provided intermediate 11-c as a beige oil.

Step 3: Intermediate 11-d

To a solution of intermediate 11-c (3.2 g, 12.02 mmol) in MeOH (25.0 ml)was added 4N HCl in 1,4-dioxane (10.95 ml, 361.0 mmol) and the reactionwas stirred overnight at room temperature. Volatiles were removed invacuo. Diethyl ether was added to the residue; a precipitate formed andwas collected by filtration to provide intermediate 11-d.HCl as a whitesolid.

Synthesis of Compound 4:

Step 1: Intermediate 12-a

To a solution of intermediate 11-d (120 mg, 0.54 mmol) and intermediate9-d (187 mg, 0.54 mmol) in 1,4-dioxane were sequentially addedN,N-dimethylglycine (167 mg, 1.62 mmol), cesium carbonate (528 mg, 1.62mmol) and copper(I) iodide (103 mg, 0.54 mmol). The reaction was stirredat reflux overnight and then cooled to room temperature. Ethyl acetatewas added, the reaction was filtered over celite. Water was added to thefiltrate, the organic layer was separated, washed with brine, dried overMgSO₄, filtered and concentrated under reduced pressure to provideintermediate 12-a as a brown solid.

Step 2: Compound 4

To a solution of intermediate 12-a (250 mg, 0.51 mmol) in EtOH (6.0 ml)was added formamidine acetate (426 mg, 4.09 mmol) and the reaction wasstirred at 80° C. for 3 hours and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 4.2HCl as a white solid. MS (m/z) M+H=516.2

Synthesis of Intermediate 13-c:

Step 1: Intermediate 13-b

To a solution of intermediate 8-c (1.43 g, 5.89 mmol) and(2-methyloxazol-5-yl)methanol (1.0 g, 8.84 mmol) in THF (20 ml) weresequentially added triphenylphosphine (2.32 g, 8.84 mmol) and DIAD (1.72ml, 8.84 mmol) at room temperature. The reaction was then stirred atroom temperature for 1 hour. Volatiles were removed under reducedpressure. Purification by silica gel chromatography providedintermediate 13-b as a yellow oil.

Step 2: Intermediate 13-c

To a solution of intermediate 13-b (1.10 g, 3.26 mmol) in THF (32 ml)was added a 1.0 M solution of TBAF in THF (3.59 ml, 3.59 mmol) and thereaction was stirred at room temperature for 1 hour. A saturated aqueoussolution of ammonium chloride and ethyl acetate were added, the organiclayer was separated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure. Purification by silica gelchromatography provided intermediate 13-c as a white solid.

Synthesis of Compound 5:

Step 1: Intermediate 14-a

To a solution of intermediate 13-c (129 mg, 0.57 mmol) and intermediate9-d (200 mg, 0.57 mmol) in 1,4-dioxane were sequentially addedN,N-dimethylglycine (36 mg, 0.34 mmol), cesium carbonate (375 mg, 1.15mmol) and copper(I) iodide (22 mg, 0.11 mmol). The reaction was stirredat reflux overnight and then cooled to room temperature. Ethyl acetatewas added, the reaction was filtered over celite. Water was added to thefiltrate, the organic layer was separated, washed with brine, dried overMgSO₄, filtered and concentrated under reduced pressure to provideintermediate 14-a as a brown solid.

Step 2: Compound 5

To a solution of intermediate 14-a (384 mg, 0.78 mmol) in EtOH (7.8 ml)was added formamidine acetate (653 mg, 6.28 mmol) and the reaction wasstirred at 80° C. for 3 hours and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 5.2HCl as a white solid. MS (m/z) M+H=517.2

Synthesis of Intermediate 15-b:

To a solution of 1-bromo-3-fluoro-5-iodobenzene 15-a (7.52 g, 25.0 mmol)in 1,4-dioxane (12.50 ml) was added (2-methylthiazol-5-yl)methanol 8-e(3.55 g, 27.5 mmol), 1,10-phenanthroline (901 mg, 5.0 mmol), copper (I)iodide (476 mg, 2.50 mmol) and cesium carbonate (11.40 g, 35.0 mmol).The reaction was stirred at 110° C. for 2 days and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite. Asaturated aqueous solution of ammonium chloride was added to thefiltrate, the organic layer was separated, and the aqueous phase wasextracted twice with ethyl acetate. The combined organic extracts werewashed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 15-b as a beige oil.

Synthesis of Intermediate 16-b:

To a solution of 1-bromo-3-fluoro-5-iodobenzene 15-a (5.0 g, 16.62 mmol)in toluene (8.3 ml) was added (6-methylpyridin-3-yl) methanol 16-a (2.25g, 18.28 mmol), 1,10-phenanthroline (599 mg, 3.32 mmol), copper (I)iodide (316 mg, 1.66 mmol) and cesium carbonate (7.58 g, 23.26 mmol).The reaction was stirred at 110° C. for 2 days and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite. Asaturated aqueous solution of ammonium chloride was added to thefiltrate, the organic layer was separated, and the aqueous phase wasextracted twice with ethyl acetate. The combined organic extracts werewashed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 16-b as a beige solid.

Synthesis of Intermediate 17-b:

To a solution of 1-bromo-3-fluoro-5-iodobenzene 15-a (5.0 g, 16.62 mmol)in toluene (8.3 ml) was added (2-methylpyrimidin-5-yl)methanol (2.26 g,18.28 mmol), 1,10-phenanthroline (599 mg, 3.32 mmol), copper (I) iodide(316 mg, 1.66 mmol) and cesium carbonate (7.58 g, 23.26 mmol). Thereaction was stirred at 110° C. for 2 days and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite. Asaturated aqueous solution of ammonium chloride was added to thefiltrate, the organic layer was separated, and the aqueous phase wasextracted twice with ethyl acetate. The combined organic extracts werewashed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Purification by silica gel chromatography providedintermediate 17-b as a beige solid.

Synthesis of Intermediate 18-b:

To a solution of ethyl 2-cyanoacetate 18-a (11.42 g, 101.0 mmol) inacetone (153.0 ml) was added potassium carbonate (20.94 g, 152.0 mmol)and 2-iodopropane (29.2 g, 172.0 mmol). The reaction mixture was heatedto reflux for 2 days, cooled to room temperature and diluted in a 1:1mixture of ethyl acetate/hexanes. Water was added, the organic layer wasseparated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure to provide intermediate 18-b as acolorless oil.

Synthesis of Intermediate 19-e:

Step 1: Intermediate 19-b

To a solution of 4-(benzyloxy)aniline hydrochloride 19-a (14.3 g, 60.8mmol) in 1N HCl (51.4 ml) was added dropwise a 1.0 M solution of sodiumnitrite in water (76.0 ml, 76.0 mmol) at room temperature, the mixturewas stirred for 1 hour, filtered and then added dropwise to an icecooled solution of intermediate 6-c (10.0 g, 50.7 mmol) in ethanol (13.7ml) and water (188.0 mL). The PH was maintained at 7 by adding potassiumacetate portion wise. The mixture was stirred at 0° C. for 3 hours androom temperature overnight. A saturated aqueous solution of ammoniumchloride and ethyl acetate were added, the organic layer was separated,washed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure to provide intermediate 19-b as a beige oil.

Step 2: Intermediate 19-c

To a solution of intermediate 19-b (20.3 g, 49.8 mmol) in a 1:1 mixtureof 1,4-dioxane/water (249.0 ml) cooled to 0° C. was added NaOH 10N(100.0 ml, 996.0 mmol) and the reaction was stirred at room temperaturefor 1 hour. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure.Purification by silica gel chromatography provided intermediate 19-c asa yellow solid.

Step 3: Intermediate 19-d

To a solution of intermediate 19-c (6.5 g, 19.4 mmol) in tert-butanol(97.0 ml) was added a 1.0 M solution of potassium tert-butoxide intert-butanol (40.7 ml, 40.7 mmol). After stirring for 15 minutes,bromoacetonitrile (3.37 ml, 48.4 mmol) was added and the reaction wasstirred for 3 hours at room temperature. A saturated aqueous solution ofammonium chloride and ethyl acetate were added, the organic layer wasseparated, the aqueous phase was extracted with ethyl acetate, thecombined organic extracts were washed with brine, dried over MgSO₄,filtered and concentrated under reduced pressure. Purification by silicagel chromatography provided intermediate 19-d as a beige foam.

Step 4: Intermediate 19-e

To a solution of intermediate 19-d (6.5 g, 17.36 mmol) in ethyl acetateand stirred under nitrogen was added 10% Pd/C (3.69 g, 1.73 mmol). Thereaction mixture was purged with H₂ and stirred for 1 hour under 1 atmof hydrogen. The reaction was then filtered through celite and thefiltrate was concentrated in vacuo. Volatiles were removed under reducedpressure to provide intermediate 19-e as a yellow solid.

Synthesis of Intermediate 20-d:

Step 1: Intermediate 20-a

To a solution of 4-(benzyloxy)aniline hydrochloride 19-a (10.0 g, 42.4mmol) in 1N HCl (60.6 ml) was added dropwise a 1.0 M solution of sodiumnitrite (41.9 ml, 41.9 mmol) in water at room temperature, the mixturewas stirred for 1 hour, filtered and then added dropwise to an icecooled solution of intermediate 2-c (5.0 g, 29.9 mmol) in ethanol (16.2ml) and water (222.0 mL). The PH was maintained at 7 by adding potassiumacetate portion wise. The mixture was stirred at 0° C. for 3 hours androom temperature for 1 hour. A saturated aqueous solution of ammoniumchloride and ethyl acetate were added, the organic layer was separated,washed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure to provide intermediate 20-a as a beige oil.

Step 2: Intermediate 20-b

To a solution of intermediate 20-a (10.0 g, 26.5 mmol) in a 1:1 mixtureof 1,4-dioxane/water (265.0 ml) cooled to 0° C. was added NaOH 10N (53.0ml, 530.0 mmol) and the reaction was stirred at room temperature for 1hour. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure.Purification by silica gel chromatography provided intermediate 20-b asa yellow solid.

Step 3: Intermediate 20-c

To a solution of intermediate 20-b (8.3 g, 28.8 mmol) andbromoacetonitrile (4.33 ml, 62.1 mmol) in tert-butanol (141.0 ml) wasadded a 1.0 M solution of sodium tert-butoxide in tert-butanol (56.4 ml,56.4 mmol). The reaction was slowly warmed to room temperature andstirred for 2 hours. A saturated aqueous solution of ammonium chlorideand ethyl acetate were added, the organic layer was separated, washedwith brine, dried over MgSO₄, filtered and concentrated under reducedpressure. Purification by silica gel chromatography providedintermediate 20-c as a beige foam.

Step 4: Intermediate 20-d

To a solution of intermediate 20-c (3.72 g, 10.38 mmol) in ethyl acetateand stirred under nitrogen was added 10% Pd/C (2.20 g, 1.03 mmol). Thereaction mixture was purged with H₂ and stirred for 1 hour under 1 atmof hydrogen. The reaction was then filtered through celite and thefiltrate was concentrated in vacuo. Volatiles were removed under reducedpressure to provide intermediate 20-d as a yellow solid.

Synthesis of Intermediate 21-d:

Step 1: Intermediate 21-a

To a solution of 4-(benzyloxy)aniline hydrochloride 19-a (20.0 g, 85.0mmol) in 1N HCl (71.8 ml) was added dropwise a 1.0 M solution of sodiumnitrite (99.0 ml, 99.0 mmol) in water at room temperature, the mixturewas stirred for 1 hour, filtered and then added dropwise to an icecooled solution of intermediate 18-b (10.0 g, 70.8 mmol) in ethanol(19.1 ml) and water (263.0 mL). The PH was maintained at 7 by addingsodium acetate portion wise. The mixture was stirred at 0° C. for 3hours and room temperature overnight. A saturated aqueous solution ofammonium chloride and ethyl acetate were added, the organic layer wasseparated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure to provide intermediate 21-a as abeige oil.

Step 2: Intermediate 21-b

To a solution of intermediate 21-a (24.0 g, 68.3 mmol) in a 1:1 mixtureof 1,4-dioxane/water (341.0 ml) cooled to 0° C. was added NaOH 10N(137.0 ml, 1366.0 mmol) and the reaction was stirred at room temperaturefor 1 hour. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure toprovide intermediate 21-b as a yellow solid.

Step 3: Intermediate 21-c

To an ice cooled solution of intermediate 21-b (8.28 g, 28.2 mmol) intert-butanol (141.0 ml) was added a 1.0 M solution of sodiumtert-butoxide in tert-butanol (56.4 ml, 56.4 mmol). After stirring for15 minutes, bromoacetonitrile (4.33 ml, 62.1 mmol) was added; thereaction was slowly warmed to room temperature and stirred for 2 hours.A saturated aqueous solution of ammonium chloride and ethyl acetate wereadded, the organic layer was separated, washed with brine, dried overMgSO₄, filtered and concentrated under reduced pressure. Purification bysilica gel chromatography provided intermediate 21-c as a yellow solid.

Step 4: Intermediate 21-d

To a solution of intermediate 21-c (5.84 g, 17.57 mmol) in ethyl acetateand stirred under nitrogen was added 10% Pd/C (1.87 g, 0.87 mmol). Thereaction mixture was purged with H₂ and stirred for 1 hour under 1 atmof hydrogen. The reaction was then filtered through celite and thefiltrate was concentrated in vacuo. Purification by silica gelchromatography provided intermediate 21-d as a yellow solid.

Synthesis of Compound 14:

Step 1: Intermediate 22-a

To a solution of intermediate 19-e (375.0 mg, 1.32 mmol) in 1,4-dioxane(1.7 ml) was added intermediate 16-b (391 mg, 1.32 mmol),N,N-dimethylglycine (272 mg, 2.64 mmol), copper (I) iodide (166 mg, 0.87mmol) and cesium carbonate (1.72 g, 5.28 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 22-a as a beige foam.

Step 2: Compound 14

To a solution of intermediate 22-a (275 mg, 0.55 mmol) in methanol (5.5ml) was added formamidine acetate (401 mg, 3.85 mmol) and the reactionwas stirred at reflux overnight and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HO/methanol gradientprovided compound 14.2HCl as a white solid. MS (m/z) M+H=527.2

Synthesis of Compound 15:

Step 1: Intermediate 23-a

To a solution of intermediate 19-e (375 mg, 1.32 mmol) in 1,4-dioxane(1.7 ml) was added intermediate 17-b (392 mg, 1.32 mmol),N,N-dimethylglycine (272 mg, 2.64 mmol), copper (I) iodide (166 mg, 0.87mmol) and cesium carbonate (1.72 g, 5.28 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 23-a as a beige foam.

Step 2: Compound 15

To a solution of intermediate 23-a (260 mg, 0.52 mmol) in methanol (5.2ml) was added formamidine acetate (541 mg, 5.19 mmol) and the reactionwas stirred at reflux overnight and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 15.2HCl as a white solid. MS (m/z) M+H=528.1

Synthesis of Compound 7:

Step 2: Intermediate 24-a

To a solution of intermediate 20-d (533.0 mg, 1.98 mmol) in 1,4-dioxane(1.0 ml) was added intermediate 15-b (600 mg, 1.98 mmol),N,N-dimethylglycine (410 mg, 3.97 mmol), copper (I) iodide (250 mg, 1.31mmol) and cesium carbonate (2.59 g, 7.94 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 24-a as a beige oil.

Step 2: Compound 7

To a solution of intermediate 24-a (470.0 mg, 0.96 mmol) in ethanol(9.60 ml) was added formamidine acetate (800 mg, 7.68 mmol) and thereaction was stirred at 80° C. for 3 hours and then cooled to roomtemperature. Volatiles were removed under reduced pressure. Purificationby reverse phase chromatography eluting with a 0.1% aqueous HCl/methanolgradient provided compound 7.2HCl as a yellow solid. MS (m/z) M+H=517.1

Synthesis of Compound 6:

Step 1: Intermediate 25-a

To a solution of intermediate 20-d (200 mg, 0.74 mmol) in 1,4-dioxane(1.0 ml) was added intermediate 16-b (221 mg, 0.74 mmol),N,N-dimethylglycine (231 mg, 3.23 mmol), copper (I) iodide (142 mg, 0.74mmol) and cesium carbonate (971 mg, 2.98 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 25-a as beige foam.

Step 2: Compound 6

To a solution of intermediate 25-a (360 mg, 0.74 mmol) in ethanol (7.45ml) was added formamidine acetate (620 mg, 5.96 mmol) and the reactionwas stirred at 80° C. for 3 hours and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 6.2HCl as a yellow solid. MS (m/z) M+H=511.2

Synthesis of Compound 8:

Step 1: Intermediate 26-a

To a solution of intermediate 20-d (542 mg, 2.02 mmol) in 1,4-dioxane(2.70 ml) was added intermediate 17-b (600 mg, 2.02 mmol),N,N-dimethylglycine (416 mg, 4.04 mmol), copper (I) iodide (254 mg, 1.33mmol) and cesium carbonate (1.97 g, 6.06 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 26-a as a beige foam.

Step 2: Compound 8

To a solution of intermediate 26-a (420 mg, 0.86 mmol) in ethanol (8.6ml) was added formamidine acetate (722 mg, 6.93 mmol) and the reactionwas stirred at 80° C. for 3 hours and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 8.2HCl as a yellow solid. MS (m/z) M+H=512.1

Synthesis of Compound 9:

Step 1: Intermediate 27-a

To a solution of intermediate 21-d (2.30 g, 9.49 mmol) in 1,4-dioxane(12.7 ml) was added intermediate 15-b (2.87 g, 9.49 mmol),N,N-dimethylglycine (1.95 g, 19.0 mmol), copper (I) iodide (1.19 g, 6.27mmol) and cesium carbonate (12.37 g, 38.0 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 27-a as a beige oil.

Step 2: Compound 9

To a solution of intermediate 27-a (1.65 g, 3.56 mmol) in ethanol (7.2ml) was added formamidine acetate (741 mg, 6.93 mmol) and the reactionwas stirred at 80° C. overnight and then cooled to room temperature.Water and ethyl acetate were added, the organic layer was separated,washed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Volatiles were removed under reduced pressure.Purification by silica gel chromatography provided compound 9 as a whitesolid. Compound 9 was dissolved in methanol, the solution was acidifiedwith 1N HCl in MeOH, a precipitated formed and was collected byfiltration to provide compound 9.2HCl as a white solid. MS (m/z)M+H=491.1

Synthesis of Compound 11:

Step 1: Intermediate 28-a

To a solution of intermediate 21-d (491 mg, 2.03 mmol) in 1,4-dioxane(2.7 ml) was added intermediate 16-b (600 mg, 2.03 mmol),N,N-dimethylglycine (418 mg, 4.05 mmol), copper (I) iodide (255 mg, 1.33mmol) and cesium carbonate (2.64 g, 8.10 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 28-a as a beige foam.

Step 2: Compound 11

To a solution of intermediate 28-a (510 mg, 1.11 mmol) in methanol (11.1ml) was added formamidine acetate (1.16 g, 11.15 mmol), the reaction wasstirred at reflux overnight and volatiles were removed under reducedpressure. Purification by reverse phase chromatography eluting with a0.1% aqueous HCl/methanol gradient provided compound 11.2HCl as a whitesolid. MS (m/z) M+H=485.2

Synthesis of Compound 10:

Step 1: Intermediate 29-a

To a solution of intermediate 21-d (2.0 g, 8.26 mmol) in 1,4-dioxane(11.0 ml) was added intermediate 17-b (2.45 g, 8.26 mmol),N,N-dimethylglycine (1.7 g, 16.5 mmol), copper (I) iodide (1.0 g, 5.45mmol) and cesium carbonate (10.76 g, 33.0 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 29-a as a beige foam.

Step 2: Compound 10

To a solution of intermediate 29-a (1.5 g, 3.27 mmol) in methanol (32.7ml) was added formamidine acetate (3.41 g, 32.7 mmol) and the reactionwas stirred at reflux overnight and then cooled to room temperature.Water and ethyl acetate were added, the organic layer was separated,washed with brine, dried over MgSO₄, filtered and concentrated underreduced pressure. Volatiles were removed under reduced pressure.Methanol was added to the residue; a precipitated formed and wascollected by filtration to provide compound 10 as a white solid. MS(m/z) M+H=486.2

Synthesis of Intermediate 30-a:

To a solution of 1-bromo-3-fluoro-5-iodobenzene 15-a (5.0 g, 16.62 mmol)in 1,4-dioxane (8.3 ml) was added benzyl alcohol 30-a (1.79 g, 16.62mmol), 1,10-phenanthroline (599 mg, 3.32 mmol), copper (I) iodide (316mg, 1.66 mmol) and cesium carbonate (7.58 g, 23.26 mmol). The reactionwas stirred at 110° C. for 2 days and then cooled to room temperature,diluted with ethyl acetate and filtered over celite. A saturated aqueoussolution of ammonium chloride was added to the filtrate, the organiclayer was separated, and the aqueous phase was extracted twice withethyl acetate. The combined organic extracts were washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure.Purification by silica gel chromatography provided intermediate 30-a asa beige oil.

Synthesis of Compound 12:

Step 1: Intermediate 31-a

To a solution of intermediate 21-d (370 mg, 1.52 mmol) in 1,4-dioxane(11.0 ml) was added intermediate 30-a (429 mg, 1.52 mmol),N,N-dimethylglycine (315 mg, 3.05 mmol), copper (I) iodide (192 mg, 1.0mmol) and cesium carbonate (1.99 g, 6.11 mmol). The reaction was heatedin a sealed tube at 110° C. overnight and then cooled to roomtemperature, diluted with ethyl acetate and filtered over celite.Volatiles were removed under reduced pressure. Purification by silicagel chromatography provided intermediate 31-a as a beige foam.

Step 2: Compound 12

To a solution of intermediate 31-a (130 mg, 0.29 mmol) in methanol (0.5ml) was added formamidine acetate (306 mg, 2.94 mmol) and the reactionwas stirred at reflux overnight and then cooled to room temperature.Volatiles were removed under reduced pressure. Purification by reversephase chromatography eluting with a 0.1% aqueous HCl/methanol gradientprovided compound 12.HCl as a yellow solid. MS (m/z) M+H=470.1

Synthesis of Intermediate 32-e:

Step 1: Intermediate 32-b

To a solution of 4-(benzyloxy)-2-fluoroaniline 32-a (12.0 g, 47.3 mmol)in 1N HCl (39.9 ml) was added dropwise a 1.0 M solution of sodiumnitrite (55.2 ml, 55.2 mmol) in water at room temperature, the mixturewas stirred for 1 hour, filtered and then added dropwise to an icecooled solution of intermediate 18-b (5.56 g, 39.4 mmol) in ethanol(10.6 ml) and water (146.0 mL). The PH was maintained at 7 by addingsodium acetate portion wise. The mixture was stirred at 0° C. for 3hours and room temperature overnight. A saturated aqueous solution ofammonium chloride and ethyl acetate were added, the organic layer wasseparated, washed with brine, dried over MgSO₄, filtered andconcentrated under reduced pressure to provide intermediate 32-b as abeige oil.

Step 2: Intermediate 32-c

To a solution of intermediate 32-b (15.0 g, 40.6 mmol) in a 1:1 mixtureof 1,4-dioxane/water (203.0 ml) cooled to 0° C. was added NaOH 10N (81.0ml, 812.0 mmol) and the reaction was stirred at room temperature for 1hour. A saturated aqueous solution of ammonium chloride and ethylacetate were added, the organic layer was separated, washed with brine,dried over MgSO₄, filtered and concentrated under reduced pressure toprovide intermediate 32-c as a beige oil.

Step 3: Intermediate 32-d

To a solution of intermediate 32-c (5.5 g, 17.6 mmol) in tBuOH (80 ml)at room temperature, was added a 1.0 M solution of tBuOK in tBuOH (37.1ml, 37.1 mmol). The reaction was stirred for 15 minutes at roomtemperature and bromoacetonitrile (3.08 ml, 44.2 mmol) was addeddropwise. After the addition was completed the reaction was stirred foran additional 3 hours. A saturated aqueous solution of ammonium chlorideand ethyl acetate were added, the organic layer was separated and theorganic phase was extracted twice with ethyl acetate. The combinedorganic extracts were washed with brine, dried over MgSO₄ filtered andconcentrated under reduced pressure. Purification by silica gelchromatography provided intermediate 32-d as a beige oil.

Step 4: Intermediate 32-e

To a solution of intermediate 32-d (1.0 g, 14.3 mmol) in ethyl acetateand stirred under nitrogen was added 10% Pd/C (607 mg, 0.3 mmol). Thereaction mixture was purged with H₂ and stirred for 3 hours under 1 atmof hydrogen. The reaction was then filtered through celite and thefiltrate was concentrated in vacuo. Purification by silica gelchromatography provided intermediate 32-e as a yellow solid.

Synthesis of Compound 16:

Step 1: Intermediate 33-a

To a solution of intermediate 32-e (200 mg, 0.7 mmol) in 1,4-dioxane(1.0 ml) was added intermediate 15-b (255 mg, 0.8 mmol),N,N-dimethylglycine (158 mg, 1.5 mmol), copper (I) iodide (97 mg, 0.5mmol) and cesium carbonate (1.0 g, 3.1 mmol). The reaction was heated ina sealed tube at 110° C. for 2 days and then cooled to room temperature,diluted with ethyl acetate and filtered over celite. Volatiles wereremoved under reduced pressure. Purification by silica gelchromatography provided intermediate 33-a as a beige foam.

Step 2: Compound 16

To a solution of intermediate 33-a (70 mg, 0.1 mmol) in isopropanol(10.0 ml) was added formamidine acetate (151 mg, 1.4 mmol) and thereaction was stirred at 100° C. overnight and then cooled to roomtemperature. Volatiles were removed under reduced pressure. Purificationby reverse phase chromatography eluting with a 0.1% aqueous HCl/methanolgradient provided compound 16.2HCl as a yellow solid. MS (m/z) M+H=509.1

Synthesis of Compound 17:

Step 1: Intermediate 34-a

To a solution of intermediate 32-e (200 mg, 0.7 mmol) in 1,4-dioxane(1.0 ml) was added intermediate 17-b (251 mg, 0.8 mmol),N,N-dimethylglycine (158 mg, 1.5 mmol), copper (I) iodide (97 mg, 0.5mmol) and cesium carbonate (1.0 g, 3.1 mmol). The reaction was heated ina sealed tube at 110° C. for 2 days and then cooled to room temperature,diluted with ethyl acetate and filtered over celite. Volatiles wereremoved under reduced pressure. Purification by silica gelchromatography provided intermediate 34-a as a beige foam.

Step 2: Compound 17

To a solution of intermediate 34-a (35 mg, 0.07 mmol) in isopropanol(10.0 ml ml) was added formamidine acetate (76 mg, 0.7 mmol) and thereaction was stirred at reflux overnight and then cooled to roomtemperature. Volatiles were removed under reduced pressure. Purificationby reverse phase chromatography eluting with a 0.1% aqueous HCl/methanolgradient provided compound 17.2HCl as a yellow solid. MS (m/z) M+H=504.1

TABLE 1 Example Compounds of Formula 1 Compound Structure MS (m/z) 1

[M + H]⁺ = 485.2 2

[M + H]⁺ = 499.2 3

[M + H]⁺ = 533.1 4

[M + H]⁺ = 516.2 5

[M + H]⁺ = 517.2 6

[M + H]⁺ = 511.2 7

[M + H]⁺ = 517.1 8

[M + H]⁺ = 512.1 9

[M + H]⁺ = 491.1 10

[M + H]⁺ = 486.2 11

[M + H]⁺ = 485.2 12

[M + H]⁺ = 470.1 13

[M + H]⁺ = 512.1 14

[M + H]⁺ = 527.2 15

[M + H]⁺ = 528.1 16

[M + H]⁺ = 509.1 17

[M + H]⁺ = 504.1

Kinase Binding Btk Kinase Inhibition Assay

Fluorescence polarization-based kinase assays were performed in 384well-plate format using histidine tagged recombinant human full-lengthBruton Agammaglobulinemia Tyrosine Kinase (Btk) and a modified protocolof the KinEASE™ FP Fluorescein Green Assay supplied from Millipore.Kinase reaction were performed at room temperature for 60 minutes inpresence of 250 μM substrate, 10 μM ATP and variable test articleconcentrations. The reaction was stopped with EDTA/kinease detectionreagents and the polarization measured on a Tecan 500 instrument. Fromthe dose-response curve obtained, the IC₅₀ was calculated using GraphPad Prisms® using a non linear fit curve. The Km for ATP on each enzymewas experimentally determined and the Ki values calculated using theCheng-Prusoff equation (see: Cheng Y, Prusoff WH. (1973) Relationshipbetween the inhibition constant (K1) and the concentration of inhibitorwhich causes 50 percent inhibition (I₅₀) of an enzymatic reaction”.Biochem Pharmacol 22 (23): 3099-108).

k_(i) values are reported in Table 2:

TABLE 2 Inhibition of Btk Compound k_(i) (nM) 1 a 2 a 3 a 4 a 5 a 6 a 7a 8 a 9 a 10 a 11 a 12 a 13 a 14 a 15 a 16 — 17 — a - Ki <100 nM; b -100 nM < Ki < 1000 nM, c - ki >1000 nM

Splenic Cell Proliferation Assay

Splenocytes were obtained from 6 week old male CD1 mice (Charles RiverLaboratories Inc.). Mouse spleens were manually disrupted in PBS andfiltered using a 70 um cell strainer followed by ammonium chloride redblood cell lysis. Cells were washed, resuspended in Splenocyte Medium(HyClone RPMI supplemented with 10% heat-inactivated FBS, 0.5×non-essential amino acids, 10 mM HEPES, 50 uM beta mercaptoethanol) andincubated at 37° C., 5% CO₂ for 2 h to remove adherent cells. Suspensioncells were seeded in 96 well plates at 50,000 cells per well andincubated at 37° C., 5% CO₂ for 1 h. Splenocytes were pre-treated intriplicate with 10,000 nM curves of Formula 1 compounds for 1 h,followed by stimulation of B cell proliferation with 2.5 ug/ml anti-IgMF(ab′)₂ (Jackson ImmunoResearch) for 72 h. Cell proliferation wasmeasured by Cell Titer-Glo Luminescent Assay (Promega). EC₅₀ values (50%proliferation in the presence of compound as compared to vehicle treatedcontrols) were calculated from dose response compound curves usingGraphPad Prism Software.

EC₅₀ values are reported in Table 3:

TABLE 3 Inhibition of splenic cell proliferation Compound EC₅₀ (nM) 1 a2 a 3 a 4 a 5 a 6 a 7 a 8 a 9 a 10 a 11 a 12 a 13 a 14 a 15 — 16 — 17 —a - EC₅₀ <100 nM; b - 100 nM < EC₅₀ < 1000 nM, c - EC₅₀ >1000 nM

Methods: Mouse Arthus

Mouse Arthus studies were conducted as reported in Braselmann S, TaylorV, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C,Wong B R, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, SinghR, Grossbard E B, Payan D G, Masuda E S: R406 an orally available spleentyrosine kinase inhibitor blocks fc receptor signaling and reducesimmune-complex mediated inflammation. J Pharmacol Exp Ther, 2006,319:998-1008.

In summary, female Balb/c mice (6-7 weeks on arrival) were habituated tothe animal facility for at least 4 days. On the day of the experiment,animals were pre-treated (t=minus 1 h) with compound or vehicle alone bygavage (PO). At t=0, animals were injected intravenously (IV; 0.1mL/mouse) with saline containing chicken ovalbumin and Evan's blue (10mg/mL of each). Ten minutes later (t=10 min), animals were anesthesizedwith isoflurane, the dorsal surface was shaved and rabbit anti-chickenovalbumin antibody was then injected intradermally at one site on theright side of the animal (25 μg in 30 μL). The same amount of isotypecontrol antibody was then injected on the left side.

The animals were then returned to their home cage and skin punches (8mm) were collected from each injection site four hours later. Thesamples were placed in 1 mL formamide overnight at 80 degrees C. (1 skinbiopsy per 1 mL formamide in a glass tube). The amount of Evan's blue inthe formamide solution was then assessed by spectrophotometry (630 nm)as a measure of serum extravasation into the dermis.

Compounds 9 and 10 demonstrated efficacy when delivered orally at 30mg/kg.

1-8. (canceled)
 9. A method of treating a disease, disorder, orcondition mediated by a protein kinase, wherein the disease, disorder orcondition comprises a proliferative disease, inflammatory disease, orautoimmune disease, and wherein the disease, disorder or condition isassociated with Tec, Src and Btk kinase family members, the methodcomprising administering to a subject in need thereof a compoundaccording to Formula 1:

wherein R is selected from the group consisting of: 1) hydrogen, 2)alkyl, 3) heteroalkyl, 4) carbocyclyl, 5) heterocyclyl, wherein thealkyl, heteroalkyl, carbocyclyl and heterocyclyl may be furthersubstituted; Y is

E is oxygen, Z is

wherein Y-E-Z—W is

X¹ and X² are independently selected from hydrogen and halogen; n is aninteger from 0 to 2; m is an integer from 0 to 2; m′ is an integer from0 to 2; W is selected from the group consisting of: W is selected fromthe group consisting of: 1) halogen, 2) aralkyl, 3) heteroaralkyl, 4)—OR³, 5) —OC(O)R⁴, 6) —OC(O)NR⁵R⁶, 7) —CH₂O—R⁴, 8) —NR⁵R⁶ 9) —NR²C(O)R⁴,10) —NR²S(O)_(n)R⁴, 11) —NR²C(O)NR⁵R⁶, wherein the, aralkyl andheteraralkyl may be further substituted; R² is selected from the groupconsisting of hydrogen and alkyl; R³ is selected from the groupconsisting of substituted alkyl, unsubstituted alkyl, alkenyl, alkynyl,heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aralkyl, andheteroaralkyl; R⁴ is selected from the group consisting of substitutedalkyl, unsubstituted alkyl, alkenyl, alkynyl, heteroalkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl; and R⁵ and R⁶ are (i) independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,heteroalkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl; or (ii)fused to form a 3 to 8 membered heterocyclyl ring system; or apharmaceutically acceptable salt, or solvate thereof.
 10. The method ofclaim 9, wherein the disease, disorder or condition comprises anautoimmune disease.
 11. The method of claim 9, wherein the disease,disorder or condition comprises inflammation.
 12. The method of claim 9,wherein the disease, disorder or condition comprises arthritis, orimmune hypersensitivity.
 13. The method of claim 9, wherein the disease,disorder or condition comprises cancer, or is characterized byinflammation or cell proliferation.
 14. The method of claim 9, whereinthe disease, disorder or condition comprises solid tumors, hematologicalmalignancies, arthritis, graft versus host disease, lupus erythematosus,psoriasis, colitis, illeitis, multiple sclerosis, uveitis, coronaryartery vasculopathy, systemic sclerosis, atherosclerosis, asthma,transplant rejection, allergy, dermatomyositis, or pemphigus.
 15. Amethod of treating a subject suffering from a protein kinase mediateddisease or condition comprising administering to the subject apharmaceutical composition comprising a compound of Formula 1, or apharmaceutically acceptable salt, or solvate thereof, effective for thetreatment, wherein the disease, disorder or condition is associated withTec, Src and Btk kinase family members.
 16. The method of claim 15,wherein the disease, disorder or condition is associated with Btk kinasefamily members.
 17. The method of claim 15, wherein the pharmaceuticalcompositions may be in a conventional pharmaceutical form suitable fororal administration selected from tablets, capsules, granules, powdersand syrups; parenteral administration as: intravenous, intramuscular, orsubcutaneous injections; drop infusion preparations, inhalation, eyelotion, topical administration, ointment, or suppositories.
 18. Themethod of treating according to claim 15, wherein the enzymatic activityof Btk is reduced by administering to a subject suffering from a proteinkinase mediated disease or condition a therapeutically effective amountof a compound of Formula 1, or a pharmaceutically acceptable salt, orsolvate thereof, alone or in combination with one or more another activeingredients.
 19. A method of modulating target kinase function, whereinsaid modulating comprises inhibiting said target kinase function, themethod comprising administering to a subject in need of such modulationa compound according to Formula 1

wherein R is selected from the group consisting of: 1) hydrogen, 2)alkyl, 3) heteroalkyl, 4) carbocyclyl, 5) heterocyclyl, wherein thealkyl, heteroalkyl, carbocyclyl and heterocyclyl may be furthersubstituted; Y is

E is oxygen, Z is

wherein Y-E-Z—W is

X¹ and X² are independently selected from hydrogen and halogen; n is aninteger from 0 to 2; m is an integer from 0 to 2; m′ is an integer from0 to 2; W is selected from the group consisting of: W is selected fromthe group consisting of: 1) halogen, 2) aralkyl, 3) heteroaralkyl, 4)—OR³, 5) —OC(O)R⁴, 6) —OC(O)NR⁵R⁶, 7) —CH₂O—R⁴, 8) —NR⁵R⁶ 9) —NR²C(O)R⁴,10) —NR²S(O)—R⁴, 11) —NR²C(O)NR⁵R⁶, wherein the, aralkyl andheteraralkyl may be further substituted; R² is selected from the groupconsisting of hydrogen and alkyl; R³ is selected from the groupconsisting of substituted alkyl, unsubstituted alkyl, alkenyl, alkynyl,heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aralkyl, andheteroaralkyl; R⁴ is selected from the group consisting of substitutedalkyl, unsubstituted alkyl, alkenyl, alkynyl, heteroalkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl; and R⁵ and R⁶ are (i) independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,heteroalkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl; or (ii)fused to form a 3 to 8 membered heterocyclyl ring system; or apharmaceutically acceptable salt, or solvate thereof.
 20. The methodaccording to claim 9, wherein method of inhibiting protein kinaseactivity, comprising administering to a human or animal subject aneffective amount of a compound of Formula I, or a pharmaceuticallyacceptable salt or solvate thereof.